Bio Platforms

GATC Health & Liquid Biosciences: Faster, Cheaper, More Effective Drug Discovery

Ian Jenkins, Director of Science, and Jeff Moses, CMO at GATC Health, discuss the combined benefits of their MAT platform and Liquid Biosciences’ Emerge mathematical evolution platform to help identify the right biology sooner and focus on a smaller set of potential compounds early in the pre-clinical development process to enable pharma companies to develop drugs with more efficiency and a higher success rate.

EXCLUSIVE ONLINE CONTENT

1/25/2022

Biomea Fusion Announces First Patient Dosed

Biomea Fusion, Inc. recently announced the first patient has been dosed in its Phase 1 clinical trial evaluating BMF-219, the company’s irreversible covalent menin inhibitor, in patients with….